Table 1.
Patients’ characteristics
| Landiolol | Control | |
| n | 39 | 22 |
| Age, yr | 70.7 ± 12.3 | 70.8 ± 12.5 |
| Underlying disease | ||
| Cardiovascular disease | 16 (41.0%) | 11 (50.0%) |
| Malignancy | 11 (28.2%) | 3 (13.6%) |
| Immunological disorder | 3 (7.7%) | 2 (9.1%) |
| Others | 9 (23.1%) | 6 (27.2%) |
| Infected site | ||
| Respiratory tract | 17 (43.6%) | 14 (63.6%) |
| Intra-abdominal | 13 (33.3%)a | 2 (9.1%) |
| Blood | 5 (12.8%) | 0 (0%) |
| Skin/soft tissue | 2 (5.1%) | 0 (0%) |
| Urinary tract | 1 (2.6%)a | 4 (18.2%) |
| Others | 1 (2.6%) | 2 (9.1%) |
| APACHE II | 22.8 ± 5.4 | 22.1 ± 7.7 |
| SOFA | 8.8 ± 4.0 | 9.1 ± 3.9 |
a
P < 0.05 vs control. APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment.